Similarly, the cytotoxic anti-neoplatic potency of gemcibatine-(C4-amide)-[anti-HER2/neu] could have alternatively been measured against an entirely different neoplastic cell type that has a relatively higher sensitivity to gemcitabine such as pancreatic carcinoma [60], small-cell lung carcinoma [61], neuroblastoma [62], or leukemia/lymphoid [63,64]. This evidence concerns the gene ERBB2 and neuroblastoma.